Within SADC, Tanzania confirms resistance to key treatments, raising concerns about the rise of drug-resistant malaria in Zambia and Namibia.
South Africa has received lenacapavir, yet the rollout is facing delays that could impact access to this crucial treatment.
South Africa may build the factories for lenacapavir, but licensing decisions, pricing, and supply remain dependent on Gilead, exposing the limits of sovereignty in global health.
Malaria-transmitting mosquitoes don’t occur in Gauteng, thus people infected with malaria cannot pass the disease on to others.
Lenacapavir promised to change the course of the epidemic, but a limited, geographically selective rollout exposes a harder reality: who gets protected, who is left behind, and whether this is ...
The recent heavy rains and associated flooding further exacerbated malaria efforts in several countries recovering from the 2025 upsurges.
By supporting Health-e News with a monthly or one-off donation, you become a vital part of sustaining independent, reliable reporting that holds the powerful accountable and empowers communities with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results